ArticleBMC geriatrics2025
Impact of fatty liver index and metabolic dysfunction-associated steatotic liver disease on the risk of benign prostatic hyperplasia in older male adults.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThe objective of this study was to ascertain whether the fatty liver index (FLI) and metabolic dysfunction-associated steatotic liver disease (MASLD) are independent risk factors for benign prostatic hyperplasia (BPH) in older men, and to evaluate their clinical utility in risk stratification.
methodsThe data utilized in this study were obtained from the National Health and Nutrition Examination Survey. After meticulous screening, 1,875 older male participants were included in the analysis. The relationships between FLI, MASLD, and BPH were examined by constructing multivariable logistic regression models, with the potential confounding variables considered. Furthermore, the dose-response relationships between FLI and BPH were investigated using restricted cubic spline curve (RCS) modeling, and subgroup analyses were conducted further to assess the differences in these relationships across populations.
resultsThe findings revealed a statistically significant positive correlation between FLI and BPH, controlling for potential confounding variables. Furthermore, the risk of BPH increased markedly with increasing quartiles of FLI. Additionally, patients with MASLD exhibited a markedly elevated risk of BPH compared to non-MASLD participants. Furthermore, RCS analysis corroborated the linear positive association between FLI and BPH.
conclusionFLI and MASLD may be valuable tools for BPH risk assessment and contribute to the development of new prevention and treatment strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.